Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2020-08-12 Transaction in Own Shar…
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 5 de agosto y el 11 de agosto de 2020.
Transaction in Own Shares Classification · 99% confidence The document is a formal communication to the Spanish National Securities Market Commission ("Comisión Nacional del Mercado de Valores") dated August 12, 2020. The subject is "Programas de recompra de acciones, estabilización y autocartera" (Share repurchase programs, stabilization, and treasury stock). It details transactions made under a previously announced Share Repurchase Program between August 5 and August 11, 2020, including tables listing the number of shares bought and the average price. This activity directly relates to the company buying back its own shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). It is not a general regulatory filing (RNS) because it is highly specific to share repurchase activity.
2020-08-12 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 29 de julio y el 4 de agosto de 2020.
Transaction in Own Shares Classification · 98% confidence The document is a formal communication to the 'Comisión Nacional del Mercado de Valores' (Spanish securities market regulator) dated August 5, 2020. The subject is 'Programas de recompra de acciones, estabilización y autocartera' (Share repurchase programs, stabilization, and treasury stock). It details transactions conducted under a previously announced Share Repurchase Program between July 29 and August 4, 2020, including tables listing the number of shares bought and the average price. This activity directly relates to the company buying back its own shares. According to the definitions, 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although it is a report of transactions, it is not a general regulatory filing (RNS) because a more specific category exists. It is not a Director's Dealing (DIRS) as it concerns the company itself, not individual directors. Therefore, POS is the most appropriate classification.
2020-08-05 English
La Sociedad envía nota de prensa relativa a los resultados del primer semestre del ejercicio 2020.
Earnings Release Classification · 100% confidence The document is an initial announcement of financial results for the first half of 2020 (period ending June 30, 2020). It provides key highlights such as net profit, total revenue, sales growth in oncology and diagnostics, and cash position. It follows the standard format of an earnings release, focusing on summary financial performance rather than a full comprehensive interim report or a regulatory filing announcement. Therefore, it is classified as an Earnings Release (ER). H1 2020
2020-07-30 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 22 de julio y el 28 de julio de 2020.
Transaction in Own Shares Classification · 99% confidence The document is a formal communication to the 'Comisión Nacional del Mercado de Valores' (Spanish Securities Market Commission) dated July 29, 2020. The subject is 'COMUNICACIÓN DE OTRA INFORMACIÓN RELEVANTE' concerning 'Programas de recompra de acciones, estabilización y autocartera' (Share repurchase programs, stabilization, and treasury stock). It details specific 'Compra' (Buy) operations of the company's own shares (autocartera) conducted between July 22 and July 28, 2020, including transaction dates, number of shares, and prices, with a detailed annex. This activity directly corresponds to the definition of a company reporting transactions in its own shares, which maps to the 'Transaction in Own Shares' category.
2020-07-29 English
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 15 de julio y el 21 de julio de 2020
Transaction in Own Shares Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. The title is 'COMUNICACIÓN DE OTRA INFORMACIÓN RELEVANTE' (Communication of Other Relevant Information) and the subject is 'Programas de recompra de acciones, estabilización y autocartera' (Share repurchase programs, stabilization, and treasury stock). The text details specific 'Compra' (Buy) operations of the company's own shares ('autocartera') conducted between July 15 and July 21, 2020, including transaction dates, volume, and price. This activity directly corresponds to the definition of a company buying back its own shares, which maps precisely to the 'Transaction in Own Shares' category. Filing Code: POS (Transaction in Own Shares).
2020-07-22 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS" (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities (PDMR) and Persons Closely Associated with Them). This form explicitly details transactions (purchases of shares) made by a director ('CONSEJERA') of the issuer (PHARMA MAR, S.A.). This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS.
2020-07-20 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.